Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1B | Q00975 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4996746 | 1.00 | CACNA1B (0.40) | CACNA1BALDH1A1ALOX15LMNAHSD17B10 | |
| SCHEMBL24425895 | 0.83 | ALDH1A1 (0.34) | ALDH1A1ALOX15LMNAHSD17B10 | |
| SCHEMBL29018522 | 0.83 | CACNA1B (0.40) | CACNA1BLMNA | |
| SCHEMBL28450584 | 0.82 | CACNA1B (0.38) | CACNA1BALDH1A1EPHX1EPHX2NPSR1 | |
| SCHEMBL1646209 | 0.82 | CACNA1B (0.38) | CACNA1BALDH1A1LMNAEPHX1EPHX2 | |
| SCHEMBL10438900 | 0.81 | ALDH1A1 (0.35) | ALDH1A1ALOX15LMNAHSD17B10EPHX1 | |
| SCHEMBL28770860 | 0.81 | ALDH1A1 (0.41) | CACNA1BALDH1A1EPHX1 | |
| SCHEMBL28743600 | 0.80 | ALDH1A1 (0.38) | CACNA1BALDH1A1LMNAEPHX2 | |
| SCHEMBL11830467 | 0.77 | CACNA1B (0.35) | CACNA1BALDH1A1LMNAEPHX1 | |
| SCHEMBL11830470 | 0.77 | CACNA1B (0.35) | CACNA1BALDH1A1LMNAEPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8558012-B2 | 2-fluoro-1,3-benzodithiol 1,1,3,3-tetraoxide derivative, production method thereof, and production method of monofluoromethyl group-containing compound using the same | NAGOYA INSTITUTE OF TECHNOLOGY (JP) | 2013-10-15 | — | — | US | disclosed |
| US-20110319637-A1 | 2-FLUORO-1,3-BENZODITHIOL 1,1,3,3-TETRAOXIDE DERIVATIVE, PRODUCTION METHOD THEREOF, AND PRODUCTION METHOD OF MONOFLUOROMETHYL GROUP-CONTAINING COMPOUND USING THE SAME | NAGOYA INSTITUTE OF TECHNOLOGY (JP) | 2011-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319637-A1 | 2-FLUORO-1,3-BENZODITHIOL 1,1,3,3-TETRAOXIDE DERIVATIVE, PRODUCTION METHOD THEREOF, AND PRODUCTION METHOD OF MONOFLUOROMETHYL GROUP-CONTAINING COMPOUND USING THE SAME | CBR1, CYP1B1, CYP2F1 | CACNA1B 1372/4885ALDH1A1 160/4885ALOX15 1402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.